CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours
- 10 June 2016
- journal article
- computed tomography
- Published by Springer Nature in European Radiology
- Vol. 27 (3) , 918-926
Abstract
Purpose The aim of this study was to evaluate the value of computed tomography (CT) spectral imaging in assessing the therapeutic efficacy of a vascular endothelial growth factor (VEGF) receptor inhibitor AG-013736 in rabbit VX2 liver tumours. Methods Twenty-three VX2 liver tumour–bearing rabbits were scanned with CT in spectral imaging mode during the arterial phase (AP) and portal phase (PP). The iodine concentrations(ICs)of tumours normalized to aorta (nICs) at different time points (baseline, 2, 4, 7, 10, and 14 days after treatment) were compared within the treated group (n = 17) as well as between the control (n = 6) and treated groups. Correlations between the tumour size, necrotic fraction (NF), microvessel density (MVD), and nICs were analysed. Results The change of nICs relative to baseline in the treated group was lower compared to the control group. A greater decrease in the nIC of a tumour at 2 days was positively correlated with a smaller increase in tumour size at 14 days (P < 0.05 for both). The tumour nIC values in AP and PP had correlations with MVD (r = 0.71 and 0.52) and NF (r = -0.54 and -0.51) (P < 0.05 for all). Conclusions CT spectral imaging allows for the evaluation and early prediction of tumour response to AG-013736. Key Points • AG-013736 treatment response was evaluated by CT in a rabbit tumour model. • CT spectral imaging allows for the early treatment monitoring of targeted anti-tumour therapies. • Spectral CT findings correlated with vascular changes after anti-tumour therapies. • Spectral CT is a promising method for assessing clinical treatment response.Keywords
Funding Information
- National Natural Science Foundation of China (81301220)
- Medical scientific and technological project in Henan Province (201403016)
This publication has 47 references indexed in Scilit:
- Dynamical Observation on Biological Progression of VX2 Liver Tumors to Identify the Optimal Time for Intervention in Animal ModelsPLOS ONE, 2013
- Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor modelsAngiogenesis, 2012
- Electroporation-Mediated Transcatheter Arterial Chemoembolization in the Rabbit VX2 Liver Tumor ModelInvestigative Radiology, 2012
- The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenograftsInternational Journal of Cancer, 2010
- Dynamic Evolutionary Changes in Blood Flow Measured by MDCT in a Hepatic VX2 Tumor Implant over an Extended 28-day Growth Period: Time-Density Curve AnalysisAcademic Radiology, 2009
- Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and AxitinibClinical Cancer Research, 2009
- Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcomaBritish Journal of Cancer, 2008
- The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor VasculatureCancer Research, 2007
- Monitoring the treatment efficacy of the vascular disrupting agent CA4PEuropean Journal of Cancer, 2007
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005